Gilead plans to submit New Drug Application for Filgotinib to USFDA
Category: #health  By Nikita Chaurasia  Date: 2019-07-03
  • share
  • Twitter
  • Facebook
  • LinkedIn

Gilead plans to submit New Drug Application for Filgotinib to USFDA

Gilead Sciences, Inc., a biotechnology company recently provided an update about the investigational- filgotinib, selective JAK1 inhibitor, at a pre-NDA (New Drug Application) meeting with the USFDA, cite sources.

For the record, Gilead Sciences, Inc. is a US-based biotechnology firm that focuses on discovering, developing & commercializing innovative medicines in areas of medical needs that have been unmet. The company transforms & simplifies medical care for people with life-threatening illnesses across the world. The company is operational in more than 35 countries across the world and is headquartered in California.

Reportedly, the Phase 3 FINCH studies along with the ongoing Phase 2 MANTA safety study evaluating semen parameters with treatment of filgotinib in men with moderately to severely active ulcerative colitis or Crohn’s disease, were discussed by Gilead with the USFDA. As a result of the discussion, the company intends to submit the New Drug Application for filgotinib as a treatment for rheumatoid arthritis by this year.

The announcement came on the heels of announcement made earlier by Gilead Sciences to collaborate with Carna Biosciences to develop & commercialize small molecule compounds in immune oncology. The biotechnology companies have also entered into a research & development partnership to examine Carna Biosciences’ proprietary lipid kinase drug discovery platform.

As per the conditions pertaining to the license agreement, Gilead Biosciences will retrieve license from Carna Biosciences for rights to create & commercialize inhibitors against target of immuno-oncology target. In relation with this agreement, Carna Biosciences is expected to receive a payment of $20 million & is entitled to receive an additional payment of $450 million upon achievement of certain development & commercial milestones. Carna Biosciences is also expected to receive royalties on future net sales, report sources close to the matter.

Source credits: https://www.gilead.com/news-and-press/press-room/press-releases/2019/7/gilead-announces-intent-to-submit-new-drug-application-for-filgotinib-to-us-food-and-drug-administration-this-year

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

Umbilical Market trends research and projections for 2019-2025
Umbilical Market trends research and projections for 2019-2025
By Nikita Chaurasia

Umbilical Market size is driven by emerging deployment of the various subsea equipment on account of reduction in risk associated with the subsea operations. The units are used to transfer signals, energy and consumables form one end to another. The ...

Glass Insulator Market outlook with industry review and forecasts
Glass Insulator Market outlook with industry review and forecasts
By Nikita Chaurasia

Glass Insulator Market size is driven by increasing investments to renovate the existing grid infrastructure across developed countries in line with the ongoing integration of smart grid technology. Advanced expenditure for the grid networks moderniz...

Ascentage Pharma declares first patient dosed in APG-2575 trial
Ascentage Pharma declares first patient dosed in APG-2575 trial
By Nikita Chaurasia

APG-2575 created by Ascentage Pharma is one of the rare Bcl-2 selective inhibitors in active clinical studies apart from Venetoclax. Ascentage Pharma has reportedly announced that it has dosed the first patient in a phase I medical study o...